Unlocking the Value of our Pipeline for T1D March 2026

2 Forward-looking statements This presentation contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this presentation, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding the initial safety and efficacy profiles of our product candidates, statements regarding our preclinical development programs, including initial preclinical data and development plans and timelines, and statements regarding cash runway are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this presentation are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this presentation and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control, including, among others: our ability to successfully advance our current and future product candidates through development activities, preclinical studies, and clinical trials; our ability to progress our product candidates through clinical development; our ability to meet development milestones on anticipated timelines; uncertainties inherent in the results of preliminary data, pre-clinical studies and earlier-stage clinical trials, which may not be predictive of final results or the results of later-stage clinical trials; our ability to obtain clearance of our future IND or CTA submissions and commence and complete clinical trials on expected timelines, or at all; our reliance on the maintenance of certain key collaborative relationships for the manufacturing and development of our product candidates; the timing, scope and likelihood of regulatory filings and approvals, including final regulatory approval of our product candidates; the impact of geopolitical issues, trade disputes and tariffs, banking instability and inflation on our business and operations, supply chain and labor force; the performance of third parties in connection with the development of our product candidates, including third parties conducting our clinical trials as well as third-party suppliers and manufacturers; our ability to successfully commercialize our product candidates and develop sales and marketing capabilities, if our product candidates are approved; our ability to recruit and maintain key members of management and our ability to maintain and successfully enforce adequate intellectual property protection. These and other risks and uncertainties are described more fully in the “Risk Factors” section of our most recent filings with the Securities and Exchange Commission and available at www.sec.gov. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Cell Foundry and Allo-Evasion Technology High Impact Programs Focused on Execution Century Therapeutics Today © 2026 3 Cell foundry generates fully functional cells at scale • Key developmental insights allow directed differentiation of cells that function like primary cells, such as beta Islet cells and CD4+/CD8+ αβ T cells Leaders in immune evasion engineering • Allo-Evasion allows cells to co-exist with a patient’s immune system • Enables enhanced persistence and potential for re-dosing of therapy Advancing lead iPSC derived cell therapies with Allo-Evasion 5.0 toward the clinic • CNTY-813 in IND-enabling studies with potential for functional cure in Type 1 Diabetes • CNTY-308 in IND-enabling studies for treatment of B-cell-mediated diseases • Patient enrollment ongoing for CNTY-101 in Phase 1/2 CARAMEL IST in autoimmune disease Cash runway extended beyond planned key clinical milestones • CNTY-813 IND submission planned for fourth quarter of 2026 with initial clinical data expected in the second half of 2027 • CNTY-308 αβ T cell program expected to enter the clinic in 2026 • CNTY-101 preliminary clinical data from Phase 1/2 CARAMEL IST expected in 2026

4 Century pipeline focus on Type 1 Diabetes and other autoimmune disease Allo-Evasion engineered in all programs infusions in outpatient setting 1. Agreement in place for an investigator sponsored trial (IST) by Professors Georg Schett and Andreas Mackensen at Friedrich-Alexander University Erlangen-Nürnberg. Product Targets Indications Research IND-enabling Clinical Phase 1 Phase 2 Phase 3 Priority Program CNTY-813 Beta Islet cells (Allo-Evasion 5.0) Beta Islet Transplantation Type 1 Diabetes Additional Programs CNTY-308 αβ iT (Allo-Evasion 5.0) CD19 B-cell-mediated autoimmune diseases CNTY-101 iNK (Allo-Evasion 1.0) CD19 B-cell-mediated autoimmune diseases Multiple iT (Allo-Evasion 5.0) Multiple B-cell mediated autoimmune diseases, solid tumors, others CARAMEL IST1 1. Agreement in place for an investigator sponsored trial (IST) by Professors Georg Schett and Andreas Mackensen at Friedrich-Alexander University Erlangen-Nürnberg.

5 Century Executive Team Experienced leadership with a track record of driving innovation and success in cell therapy Chad Cowan, PhD Chief Scientific Officer Brent Pfeiffenberger, PharmD, MBA Chairman and Chief Executive Officer Greg Russotti, PhD Chief Technology and Manufacturing Officer Megan Bilson Chief People Officer Douglas Carr, CPA Head of Finance Principal Financial Officer Elizabeth Devlin Head of Development